Thomas Hope, MD: Gallium 68 PSMA-11 Approval for PSMA-Targeted PET Imaging of Prostate Cancer

The FDA recently approved gallium (Ga) 68 PSMA-11, a radioactive diagnostic agent, for prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging of patients with recurrent prostate cancer. Ga 68 PSMA-11, the approval of which was granted to the University of California San Francisco (UCSF) and the University of California Los Angeles (UCLA), is the first agent to be approved specifically for the detection of PSMA-positive lesions. In this interview with i3 Hea...
Continue reading

Copyright © 2021 Oncology Data Advisor. All rights reserved.